Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ILMN Stock News and Mentions of Illumina, Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Illumina Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Illumina, Inc. (ILMN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Illumina stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Illumina, Inc. (ILMN)
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Illumina ( ILMN ) Expected to Beat Earnings Estimates: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 25, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
In Article Trend: Bullish
April 19, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Can Illumina ( ILMN ) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
April 19, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 16, 2024 (14:46) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Illumina - Illumina ( NASDAQ:ILMN )
Deep-pocketed investors have adopted a bearish approach towards Illumina ILMN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
April 16, 2024 (11:11) / "Forbes" (by Robert Hart)
What To Know About G42-The Emirati AI Giant That Just Got A $1.5 Billion Investment From Microsoft
Microsoft on Tuesday announced it will invest $1.5 billion in leading United Arab Emirates artificial intelligence firm G42, the tech giant's latest high stakes investment in the sector and a sign of growing ties between Washington and Abu Dhabi as the U.S. fights to stay ahead of China in the ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (19:31) / "The Economist" (by The Economist)
America hits Chinese biotech-and its own drugmakers
A sweeping bill in Congress could cost patients at home ...
In Article Trend: Neutral
April 15, 2024 (14:55) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Gains As Elon Musk Says This 'Must Be Done,' Cathie Wood Buys Plunging Stocks
The Dow Jones index rose after Goldman Sachs ( GS ) beat views and retail sales data was strong. Tesla ( TSLA ) fell after CEO Elon Musk said massive job cuts were essential for the firm. Apple ( AAPL ) fell, while Nvidia ( NVDA ) climbed after bullish Wall Street calls.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:45) / "Benzinga" (by Benzinga Insights)
Looking Into Illumina's Recent Short Interest - Illumina ( NASDAQ:ILMN )
Illumina's ILMN short percent of float has risen 5.16% since its last report. The company recently reported that it has 5.21 million shares sold short, which is 3.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.27 days to cover their ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:00) / "PR Newswire" (by Inc.)
Illumina's planned divestment of GRAIL approved by the European Commission
SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. ( NASDAQ: ILMN ) , a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission ( EC ) .
In Article Trend: Neutral
April 10, 2024 (12:16) / "Barrons" (by Bill Alpert)
Search for Cancer Blood Test Continues After Illumina-Grail Deal Fails
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal's Failure ...
In Article Trend: Neutral
April 9, 2024 (20:05) / "PR Newswire"
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer - PR Newswire
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer PR ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:26) / "Benzinga" (by Avi Kapoor)
Jim Cramer Isn't Going With This Tech Company: 'I'm A Nvidia Guy' - Academy Sports ( NASDAQ:ASO ) , Amazon.com ( NASDAQ:AMZN )
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. UBER. "I think Uber is really well run," he noted. Uber recently entered into a new nationwide partnership with The Vitamin Shoppe, bringing the New Jersey-based health and wellness retailer's selection ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (19:43) / "Business Insider" (by Rick Orford)
Nasdaq's Nosebleed Section: 3 Expensive Stocks to Sell Before It's Too Late
The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting investors at risk of inflated stock prices and selloffs.
In Article Trend: Neutral
April 5, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Companion Diagnostics Market Worth $13.6 billion | MarketsandMarkets™
CHICAGO, April 5, 2024 /PRNewswire/ -- Companion Diagnostics Market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029 according to a new report by MarketsandMarkets™.
In Article Trend: Somewhat-Bullish
March 30, 2024 (01:45) / "PR Newswire" (by Research and Markets)
DNA Methylation Detection Technology Markets, 2033 - Intensified Competition, Increasing Adoption, PCR Dominates
DUBLIN, March 29, 2024 /PRNewswire/ -- The "Global DNA Methylation Detection Technology Market: Focus on Technology, Application, End User, Product Type, Country Level Analysis and Competitive Landscape - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
In Article Trend: Somewhat-Bullish
March 29, 2024 (10:30) / "PR Newswire" (by Research and Markets)
Global Sample Preparation Market Analysis and Outlook 2023-2030 Featuring Profiles of Agilent Technologies, Bio-Rad Labs, Danaher Corp, Illumina, Merck, and Other Key Players
Global Sample Preparation Market Analysis and Outlook 2023-2030 Featuring Profiles of Agilent Technologies, Bio ... PR ...
In Article Trend: Somewhat-Bullish
March 29, 2024 (01:30) / "PR Newswire" (by Research and Markets)
Whole Genome and Exome Sequencing Market Analysis 2023-2024 and 2027 with Executive and Consultant Guides Featuring llumina, ION, Pacific Biosystems, Roche, SOLiD, Oxford Nanopore Among Others
Whole Genome and Exome Sequencing Market Analysis 2023-2024 and 2027 with Executive and Consultant Guides ... PR ...
In Article Trend: Neutral
March 26, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Bullish
March 22, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences ( EXAS ) Up 4.2% Since Last Earnings Report: Can It Continue?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 21, 2024 (22:37) / "Motley Fool" (by Eric Volkman)
Why Illumina Stock Zoomed Higher on Thursday
The company's chances for winning an important legal battle have improved dramatically.
In Article Trend: Somewhat-Bullish
March 21, 2024 (17:56) / "Benzinga" (by Vandana Singh)
Why Is Illumina Stock Trading Higher On Thursday? - Illumina ( NASDAQ:ILMN )
In a setback for EU antitrust regulators, an adviser to Europe's top court has criticized the decision to block Illumina Inc's ILMN $7.1 billion bid for Grail Inc., stating that they exceeded their powers.
In Article Trend: Neutral
March 18, 2024 (13:44) / "Zacks Commentary" (by Zacks Investment Research)
Labcorp ( LH ) Presents New Research on Precision Diagnostics
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
In Article Trend: Neutral
March 18, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 16, 2024 (21:05) / "Motley Fool" (by Courtney Carlsen)
Is Icahn Enterprises Stock a Buy?
The stock offers an incredible dividend yield near 29%, but investors should consider the following before buying it.
In Article Trend: Somewhat-Bullish
March 16, 2024 (14:29) / "PR Newswire" (by Laboratory Corporation of America Holdings)
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker ... PR ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:20) / "Business Insider" (by Matthew Fox)
The Nvidia-led AI boom will eventually spread to these 3 areas of the stock market, Goldman says
Stock Market Outlook: Nvidia's AI Boom to Spread to 3 Groups of Stocks - Markets Insider ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:56) / "Benzinga" (by Vandana Singh)
Gene Sequencing Firm Illumina Escapes Carl Icahn's Second Proxy Battle Amid Grail Divestment Efforts What's Going On With Illumina Stock On Wednesday? - Illumina ( NASDAQ:ILMN )
Activist investor Carl Icahn has opted against pursuing a fresh challenge to Illumina Inc's ILMN board, a move that spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.
In Article Trend: Neutral
March 13, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco Biotechnology & Genome ETF ( PBE ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:00) / "PR Newswire"
Element Biosciences Announces Senior Vice President of Global Sales and Support - PR Newswire
Element Biosciences Announces Senior Vice President of Global Sales and Support PR ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:46) / "Benzinga" (by Benzinga Insights)
A Closer Look at Illumina's Options Market Dynamics - Illumina ( NASDAQ:ILMN )
Deep-pocketed investors have adopted a bearish approach towards Illumina ILMN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 7, 2024 (12:30) / "PR Newswire" (by Moligo Technologies)
Moligo Technologies Appoints John Kuijpers as Chief Business Officer
Kuijpers comes with successful track record growing sales of new technologies, as Moligo accelerates commercial expansion
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (15:00) / "Benzinga" (by Globe Newswire)
Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024
Researchers present abstracts and poster sessions showcasing research and clinical solutions
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:30) / "Benzinga" (by Globe Newswire)
Spatial Genomics & Transcriptomics Market Anticipated to Reach USD 2 billion, Rising at a CAGR of 17% by 2033: Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global spatial genomics & transcriptomics market is estimated to flourish at a CAGR of 17% from 2023 to 2033.
In Article Trend: Bullish
March 1, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should Invesco S&P 500 Equal Weight ETF ( RSP ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Neutral
February 28, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco S&P 500 Equal Weight ETF ( RSP ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website